$ABEO

Vazzano Joseph Walter sold $173K of ABEO

Vazzano Joseph Walter (Chief Financial Officer) sold 24,880 shares of ABEONA THERAPEUTICS INC. (ABEO) at $6.96 ($0.17M total) on 2026-07-09.

Original reporting
SEC EDGAR · Vazzano Joseph Walter
Published Jul 9, 2026, 11:24 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 9, 2026, 11:29 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ABEO
Neutral
medium confidence
Mentioned
$ABEO
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABEONeutralLow
01

Why it matters

The disclosure updates insider activity and can marginally affect sentiment, but it does not introduce new operational or financial guidance.

02

Market read

Traders may monitor follow-on insider activity, but this single sale is unlikely to drive a durable repricing without accompanying company catalysts.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the article provides no stated rationale.

Relevance 4/10Novelty 4/10Timing: Filed 2026-07-09, covering a same-day insider sale transaction.

Background

The article is an SEC Form 4 insider transaction for Abeona Therapeutics, reported by the CFO.

Company-level read

Ticker impact

$ABEONeutralMedium confidence
Context

Abeona Therapeutics CFO Vazzano sold 24,880 shares on 2026-07-09 at $6.9637 for about $173K, per Form 4.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing discloses transaction size and price but not a new company event (no guidance, trial, deal, or regulatory action). Insider sales are common and often non-informational, especially without additional context.

Market effects

Limited read-across to biotech sector; this is company-specific insider trading data.

No clear regional spillover implied.

Low global relevance; no deal, trial, or regulatory development disclosed.

Counterpoint

Absence of a stated 10b5-1 plan could be interpreted as less mechanical selling, which some traders may view as mildly bearish.

Key entities

  • ABEO

    Abeona Therapeutics Inc., the company whose CFO reported an open-market sale.

  • Vazzano Joseph Walter

    Chief Financial Officer who sold 24,880 shares on 2026-07-09.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ABEOMed

Abeona Therapeutics Swings To Q2 Net Loss; Shares Plunge

Abeona Therapeutics (ABEO) reported Q2 2026 results showing a swing to a net loss of $20.19M, or $0.35/share, versus net income of $108.83M, or $1.71/share, a year earlier largely due to a $152.37M priority review voucher gain. Q2 revenue rose to $11.38M from $0.40M. Cash totaled $146.8M as of June 30. ZEVASKYN treated 5 patients in Q2.

$ABEOMedAI 8/10

Why is Abeona Therapeutics stock slumping today?

Abeona Therapeutics (ABEO) shares fell 15.8% pre-open after it reported Q2 2026 results. The company posted a loss of 35 cents per share versus a year-earlier profit of $1.71, and revenue of $11.4M versus an estimated $12.2M. Revenue recognition for ZEVASKYN was limited by a manufacturing batch yield shortfall.

$ABEOMed

ABEONA THERAPEUTICS INC. (ABEO): Results of Operations and Financial Condition

ABEONA THERAPEUTICS INC. (ABEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Abeona Therapeutics ® Reports Second Quarter 2026 Results and Provides Business Update - Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since lau

$ABEOMedAI 8/10

A new CMS payment could help Medicare patients access ZEVASKYN

Abeona Therapeutics (Nasdaq: ABEO) said CMS granted ZEVASKYN (prademagene zamikeracel) NTAP status under the FY2027 Hospital Inpatient Prospective Payment System rule. Abeona said NTAP adds supplemental Medicare reimbursement for technologies showing substantial clinical improvement. The company also reiterated ZEVASKYN’s safety risks, including potential cancer risk and serious allergic reactions.